Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) and Hoth Therapeutics (NASDAQ:HOTH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.
Earnings & Valuation
This table compares Emmaus Life Sciences and Hoth Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Emmaus Life Sciences | $29.60 million | 0.04 | -$3.73 million | ($0.09) | -0.19 |
| Hoth Therapeutics | N/A | N/A | -$7.84 million | ($1.32) | -0.69 |
Emmaus Life Sciences has higher revenue and earnings than Hoth Therapeutics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Emmaus Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Hoth Therapeutics | 0 | 0 | 3 | 1 | 3.25 |
Hoth Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 336.78%. Given Hoth Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Hoth Therapeutics is more favorable than Emmaus Life Sciences.
Profitability
This table compares Emmaus Life Sciences and Hoth Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Emmaus Life Sciences | -17.11% | N/A | -12.66% |
| Hoth Therapeutics | N/A | -89.68% | -82.61% |
Insider & Institutional Ownership
7.4% of Emmaus Life Sciences shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 35.0% of Emmaus Life Sciences shares are owned by company insiders. Comparatively, 10.6% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Emmaus Life Sciences has a beta of 6.64, indicating that its stock price is 564% more volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Summary
Emmaus Life Sciences beats Hoth Therapeutics on 9 of the 14 factors compared between the two stocks.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
About Hoth Therapeutics
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
